Laneta J Dorflinger
Overview
Explore the profile of Laneta J Dorflinger including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
21
Citations
147
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Mackenzie A, Chung S, Hoppes E, Miller N, Burke A, Achilles S, et al.
Contraception
. 2025 Jan;
:110829.
PMID: 39864646
Objective: We sought to develop consensus recommendations for measurement and analysis of data on contraceptive-induced menstrual changes (CIMCs) in contraceptive clinical trials. We built upon previous standardization efforts over the...
2.
Halpern V, Wheeless A, Brache V, Lendvay A, Cochon L, Taylor D, et al.
Contracept X
. 2023 Oct;
5:100100.
PMID: 37823034
Objectives: This study aimed to evaluate and compare local tolerability of investigational drug TV-46046 and reference drug Depo-subQ Provera 104, both containing medroxyprogesterone acetate (MPA) as an active ingredient. Study...
3.
Cordova-Gomez A, Wong A, Sims L, Doncel G, Dorflinger L
Front Reprod Health
. 2023 Sep;
5:1210083.
PMID: 37674657
Nowadays there are multiple types of contraceptive methods, from reversible to permanent, for those choosing to delay pregnancy. Misconceptions about contraception and infertility are a key factor for discontinuation or...
4.
Rademacher K, Sripipatana T, Danna K, Sitrin D, Brunie A, Williams K, et al.
Glob Health Sci Pract
. 2022 Oct;
10(5).
PMID: 36316136
In 2015, a global learning agenda for the hormonal intrauterine device (IUD) was developed with priority research questions regarding use of the method in low- and middle-income countries. In addition,...
5.
Cartwright A, Mackenzie A, Callahan R, Valeria Bahamondes M, Dorflinger L
Front Glob Womens Health
. 2022 Sep;
3:992639.
PMID: 36159884
No abstract available.
6.
Taylor D, Deese J, Bahamondes L, Brache V, Veiga Jr N, Fuchs R, et al.
Contracept X
. 2022 Aug;
4:100080.
PMID: 35965654
Objective: To characterize return to ovulation after injecting Sayana Press (104 mg/0.65 mL medroxyprogesterone acetate [MPA] in the Uniject device) every 4 months for 1 year of treatment. Study Design:...
7.
Hoppes E, Nwachukwu C, Hennegan J, Blithe D, Cordova-Gomez A, Critchley H, et al.
Gates Open Res
. 2022 May;
6:49.
PMID: 35614964
: Contraceptive-induced menstrual changes (CIMCs) can affect family planning (FP) users' lives in both positive and negative ways, resulting in both opportunities and consequences. Despite this, and despite the important...
8.
Taylor D, Halpern V, Brache V, Bahamondes L, Jensen J, Dorflinger L
Contracept X
. 2022 Mar;
4:100073.
PMID: 35281554
Objectives: To characterize the relationship between serum medroxyprogesterone acetate (MPA) concentrations and ovulation suppression, and to estimate the risk of ovulation for investigational subcutaneous regimens of Depo-Provera CI (Depo-Provera) and...
9.
Halpern V, Fuchs R, Brache V, Bahamondes L, Miranda M, Lendvay A, et al.
Contracept X
. 2021 Nov;
3:100070.
PMID: 34746745
Objectives: To identify the lowest dose of Depo-Provera that, when administered off-label subcutaneously, suppressed ovulation and had a pharmacokinetic profile consistent with a 4-month contraceptive effect. Study Design: We conducted...
10.
Halpern V, Brache V, Taylor D, Lendvay A, Cochon L, Jensen J, et al.
Fertil Steril
. 2021 Jan;
115(4):1035-1043.
PMID: 33485608
Objective: To evaluate the pharmacokinetics and pharmacodynamics of medroxyprogesterone acetate after a single subcutaneous injection in the abdomen of 150 or 300 mg Depo-Provera and compare results to two injections...